United Therapeutics Corporation Share Repurchase Program Excise Tax
United Therapeutics Corporation (UTHR) reported Share Repurchase Program Excise Tax of $8.40 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Notes › Equity
us-gaap:ShareRepurchaseProgramExciseTax · last filed 2026-05-06
- United Therapeutics Corporation share repurchase program excise tax for the quarter ending 2026-03-31 was $8.40M.
- United Therapeutics Corporation share repurchase program excise tax for the quarter ending 2024-06-30 was -$500.00K.
- United Therapeutics Corporation share repurchase program excise tax for the quarter ending 2024-03-31 was $6.90M.
- United Therapeutics Corporation share repurchase program excise tax for fiscal 2025 was $1.80M, a 64.00% decline from fiscal 2024.
- United Therapeutics Corporation share repurchase program excise tax for fiscal 2024 was $5.00M.
| Period end | Share Repurchase Program Excise Tax 3 month | Share Repurchase Program Excise Tax 6 month | Share Repurchase Program Excise Tax 12 month |
|---|---|---|---|
| 2026-03-31 | $8.40M 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | $1.80M 10-K · filed 2026-02-25 | ||
| 2024-12-31 | $5.00M 10-K · filed 2026-02-25 | ||
| 2024-06-30 | -$500.00K 10-Q · filed 2024-07-31 | $6.40M 10-Q · filed 2024-07-31 | |
| 2024-03-31 | $6.90M 10-Q · filed 2025-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |